ArticleScientific reports2025
Analysis of Candida auris resistance and associated risk factors in hospitalized patients at a tertiary care hospital in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antifungal resistance and poor clinical outcome rates ofFrontiers in microbiology · 2026Pooled it
- Clinical management, antifungal susceptibility, and predictors of 28-day mortality in Candidozyma auris candidemia: A single-center cohort study.Medical mycology · 2026Article
- Risk Factors for Mortality inJournal of fungi (Basel, Switzerland) · 2026Article
- Clinical characteristics, healthcare-associated exposures, and antifungal susceptibility patterns of Candida auris colonization and invasive infections: a retrospective observational study at a single center in Turkey.BMC infectious diseases · 2026Observational
- Outcomes of patients withAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Tackling a global threat: a clinical scenario-based framework for preventing and managingFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Candida auris (Candidozyma auris, C. auris) is a significant concern in infection prevention. This study aims to analyze the antifungal susceptibility of C. auris isolates and risk factors of C. auris-associated infections in hospitalized patients at a tertiary care hospital in China, providing evidence to guide infection control strategies and effectively prevent in-hospital transmission. A retrospective analysis was conducted to evaluate the quarterly trends in newly identified Candida isolates from January 1, 2022, to March 31, 2025. Antifungal susceptibility profiles of C. auris were assessed and compared with those of other Candida species. In addition, the clinical characteristics of hospitalized patients infected with C. auris were analyzed and compared to those of patients infected with other Candida species. The number of newly identified C. auris infections demonstrated an upward trend over the study period. In our hospital, C. auris showed a fluconazole resistance rate of 77.42% and an amphotericin B resistance rate of 3.23%. Patients with C. auris infection had a significantly longer median hospital stay [17 (14-25) days] compared to those infected with other Candida species [12 (7-19) days] (p < 0.001), as well as a significantly higher mortality rate (p < 0.001). A multivariable regression analysis of Candida infections showed that intensive care unit admission (OR 1.502, 95% CI 1.273-1.923), hypertension (OR 1.476, 95% CI 1.207-1.807), immunosuppressive status (OR 1.179, 95% CI 1.036-1.483), and the presence of indwelling medical devices (OR 1.265, 95% CI 1.065-1.422) were all independently associated with infection risk, with statistical significance (p < 0.05). Ongoing vigilance is warranted for fluconazole-resistant C. auris, and stringent implementation of infection prevention and control measures remains essential to limit its spread and impact in healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.